Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam + propofol versus dexmedetomidine + propofol for sedation during transesophageal echocardiography in patients with cardiovascular disease
ChiCTR2400088103Phase 4Not yet recruiting
- Sponsor
- Shifang People's Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in cardiac morbidity comparing Remimazolam + propofol with Dexmedetomidine + propofol (2 arms). Primary endpoints: Ramsay score, VAS score and 2 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
remimazolamdexmedetomidinepropofol
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on ChiCTR2400088103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088103.